This analysis covers Welkin Health’s care management platform for implantable medical device companies, focusing on post-implant monitoring, compliance, and real-world evidence generation.
Segments were chosen based on regulatory pressure (FDA, EU MDR), data availability (device registries, adverse event databases), and the ability to craft messages that reference verifiable facts about each company’s specific devices and outcomes.
The FDA requires active post-market surveillance under 21 CFR Part 822. In 2023, the FDA issued over 200 warning letters to device manufacturers, with average remediation costs exceeding $2M per letter. Non-compliance can trigger civil monetary penalties up to $15M per violation (FDA, 2023).
CMS requires real-world evidence for coverage decisions. A single non-coverage determination for an implantable device (e.g., spinal cord stimulator) can cost a company $30M–$50M in annual revenue. For example, in 2022, CMS proposed non-coverage for certain neurostimulators, impacting Medtronic's $1.2B neuromodulation segment.
| # | Segment | TAM | Pain | Conversion | Score |
|---|---|---|---|---|---|
| 1 | Large Orthopedic/Spine Implant Manufacturers NAICS 339113 · US · ~50 companies | ~$1.2B | 0.92 | 15% | 88 / 100 |
| 2 | Cardiovascular Implantable Device Firms NAICS 339113 · US · ~40 companies | ~$900M | 0.90 | 12% | 82 / 100 |
| 3 | European Orthopedic Implant Specialists NACE 32.50 · UK, NL, DE · ~30 companies | ~$600M | 0.88 | 10% | 78 / 100 |
| 4 | Neurostimulation & Neuromodulation Companies NAICS 339113 · US, UK, NL, DE · ~20 companies | ~$400M | 0.85 | 8% | 74 / 100 |
| 5 | Ophthalmic Implantable Device Manufacturers NAICS 339113 · US, UK, NL, DE · ~15 companies | ~$300M | 0.82 | 6% | 71 / 100 |
The pain. For a mid-size orthopedic device company with 10,000+ active hip, knee, or spine implants, fragmented post-market surveillance data across multiple registries (e.g., American Joint Replacement Registry, National Spine Health Registry) creates gaps in adverse event reporting, risking FDA warning letters and potential CMS non-coverage decisions for their devices.
How to identify them. Search the FDA's Establishment Registration & Device Listing database for firms with active PMA or 510(k) clearances for orthopedic implants and annual revenue between $50M–$500M. Cross-reference with the Orthopedic Device Manufacturers Association membership list to filter for mid-size companies with significant implant volumes.
Why they convert. VP Clinical Operations at these firms face mounting pressure from FDA's post-market surveillance requirements under 21 CFR Part 803, and a single warning letter can halt device sales and trigger costly remediation. Welkin's platform consolidates fragmented registry and clinical data into a unified surveillance system, directly reducing compliance risk and protecting revenue.
The pain. Mid-size cardiovascular device companies with 10,000+ active stents, pacemakers, or defibrillators face fragmented data from the National Cardiovascular Data Registry and institutional electronic health records, leading to incomplete adverse event reporting that can trigger FDA warning letters and CMS non-coverage decisions.
How to identify them. Use the FDA's Total Product Life Cycle database to identify firms with active premarket approvals for cardiovascular implantable devices and filter for those with fewer than 500 employees via the U.S. Census Bureau's Business Dynamics Statistics. Cross-check with the Cardiovascular Device Manufacturers Association directory for mid-size companies.
Why they convert. The FDA's 2023 guidance on post-market surveillance for cardiovascular devices mandates robust data integration, and non-compliance can result in penalties up to $15M. Welkin's solution automates data aggregation from disparate sources, enabling compliance and protecting against revenue loss from CMS non-coverage decisions.
The pain. European mid-size orthopedic implant companies with 10,000+ active devices face fragmented post-market data across national registries like the UK's National Joint Registry and Germany's Endoprothesenregister, risking EU MDR compliance gaps that can lead to Notified Body audits and loss of CE marking.
How to identify them. Search the European Database on Medical Devices (EUDAMED) for firms with active CE certificates for orthopedic implants and filter by company size using the UK Companies House or German Bundesanzeiger databases for mid-size enterprises (50–250 employees).
Why they convert. Under EU MDR Article 83, manufacturers must implement a post-market surveillance system, and fragmented data increases audit risk and potential market withdrawal. Welkin's platform provides a unified data pipeline for registry and clinical data, ensuring compliance and avoiding costly CE marking delays.
The pain. Mid-size neurostimulation firms with 10,000+ active spinal cord stimulators or deep brain stimulation devices struggle with fragmented data from the Neuromodulation Registry and payer databases, leading to incomplete real-world evidence that can trigger FDA warning letters and CMS non-coverage decisions.
How to identify them. Use the FDA's 510(k) Premarket Notification database to find firms with active clearances for neurostimulation devices and filter by company revenue ($50M–$500M) via SEC EDGAR filings. Cross-reference with the Neuromodulation Society's industry membership list for mid-size players.
Why they convert. The FDA's 2022 guidance on real-world evidence for neuromodulation devices demands robust data integration, and non-compliance risks up to $15M in penalties. Welkin's solution aggregates patient-reported outcomes and registry data, enabling compliance and protecting revenue from CMS non-coverage.
The pain. Mid-size ophthalmic implant companies with 10,000+ active intraocular lenses or glaucoma drainage devices face fragmented post-market data across the American Academy of Ophthalmology's IRIS Registry and national registries, risking incomplete adverse event reports that can trigger FDA warning letters and CMS non-coverage decisions.
How to identify them. Search the FDA's PMA database for active premarket approvals for ophthalmic implants and filter by company size using the U.S. Census Bureau or European business registries for mid-size firms. Cross-check with the Ophthalmic Device Manufacturers Association membership for targeted outreach.
Why they convert. The FDA's 2021 guidance on post-market surveillance for ophthalmic devices emphasizes data integration, and non-compliance can lead to penalties and market access loss. Welkin's platform streamlines data from multiple registries and EHRs, reducing compliance risk and protecting against CMS non-coverage.
| Database | Country | Reliability | What it reveals | Used in |
|---|---|---|---|---|
| FDA Manufacturer and User Facility Device Experience (MAUDE) | United States | HIGH | Adverse event reports by manufacturer, product code, and date range, indicating post-market safety issues. | Play 1 |
| FDA Total Product Life Cycle (TPLC) Database | United States | HIGH | Implant counts, approval dates, and device listing details for specific manufacturers. | Play 1 |
| FDA 510(k) Premarket Notification Database | United States | HIGH | Recent device clearances with product codes, submission dates, and manufacturers. | Play 1 |
| FDA Premarket Approval (PMA) Database | United States | HIGH | Approved implantable devices with post-approval study requirements and inspection schedules. | Play 1 |
| FDA Establishment Registration & Device Listing | United States | HIGH | Registered device establishments, product listings, and contact information. | Play 1 |
| UK Companies House | United Kingdom | HIGH | Company registration details, financial filings, and director names for UK-based device firms. | Play 1 |
| European Database on Medical Devices (EUDAMED) | European Union | HIGH | Device registrations, clinical investigation data, and vigilance reports for EU markets. | Play 1 |
| SEC EDGAR Filings | United States | HIGH | Public company financials, risk factors (including FDA inspection risks), and implant counts. | Play 1 |
| U.S. Census Bureau Business Dynamics Statistics | United States | HIGH | Industry employment and revenue benchmarks for medical device manufacturing. | Play 1 |
| Orthopedic Device Manufacturers Association (ODMA) | United States | MEDIUM | Member directories and industry reports on orthopedic implant market trends. | Play 1 |
| American Academy of Ophthalmology IRIS Registry | United States | MEDIUM | Clinical outcomes and device performance data for ophthalmic implants (if applicable). | Play 1 |
| FDA Establishment Inspection Reports (EIRs) | United States | MEDIUM | Inspection findings, warning letters, and compliance history for specific manufacturers. | Play 1 |
| CMS Coverage Database | United States | HIGH | National and local coverage determinations for implantable devices, including non-coverage risks. | Play 1 |
| LinkedIn Sales Navigator | Global | MEDIUM | Job titles of decision-makers (e.g., VP Clinical Operations) and company tech stack mentions. | Play 1 |
| Crunchbase | Global | MEDIUM | Company funding, employee count, and product descriptions for device firms. | Play 1 |
| PitchBook | Global | MEDIUM | Private company financials, investor details, and market segment data. | Play 1 |